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THE EFFECTS OF NICE APPRAISALS ON PRESCRIBING AND COST-
SHARING BEHAVIOR IN THE US
Sepulveda B, Doyle J
Quintiles Consulting, Hawthorne, NY, USA
OBJECTIVES: As US health care increasingly looks towards proven clinical effective-
ness for reimbursement decisions, we hypothesized that HTAs published by NICE 
would inﬂ uence drug prescribing and patient cost-sharing expenditures in the US 
according to the nature of the published guidance. The primary objective was to 
determine whether trends in prescription volume (TRx) and the proportion of drug 
costs paid out-of-pocket (%OPC) of 10 drugs appraised by 7 HTAs since 2007. 
METHODS: Seven NICE HTAs since 2007, evaluating a total of 10 drugs, were 
analyzed. Six drugs were freely encouraged for utilization (lenalidomide, entecavir, 
tenofovir, donezepil, galantamine, rivastigmine), two were approved for restricted 
populations (cinacalcet, naltrexone) and the use of two of the drugs was restricted for 
all populations (telbivudine, memantine). TRx, and OPC as a percent of average retail 
price were collected quarterly for the same duration pre- and post-HTA until April 
2010 using SDI’s VONA and VOPA databases. Statistical analyses were performed 
using one-way ANOVA; statistically signiﬁ cant results had P < 0.05. RESULTS: 
Comparing the periods before and after HTA publication, three drugs with positive 
guidance showed signiﬁ cant increases in prescription volume (P < 0.05). However, 
two drugs with advised use for restricted populations, and one with a negative guid-
ance also showed signiﬁ cant increases. Interestingly, two drugs with positive guidance 
showed signiﬁ cant decreases in TRx. Only entecavir showed a signiﬁ cant decrease in 
%OPC, while all others failed to show a signiﬁ cant difference. CONCLUSIONS: 
NICE HTAs decisions appear to be associated with mixed effects on prescription 
utilization and expenditures in the United States. Though prescribing behavior was 
changed in the periods analyzed, further research is warranted to determine the true 
nature of that change. With increased cost-sharing in the health care environment in 
the US, it will be interesting to monitor the forces that might precipitate changes in 
OPC, whether related to HTA publications or not.
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VANCOMYCIN UTILIZATION EVALUATION IN A TEACHING HOSPITAL 
BETWEEN FEBRUARY 2007 AND MAY 2008 IN IRAN
Soleymani F
Tehran University of Medical Science, Tehran, Iran
OBJECTIVES: Increasing antimicrobial resistance is now a major problem in the 
world. Especially wide spectrum antibiotics resistance germs like vancomycin-resistant 
enterococci (VRE) should be dealt as soon as possible as an emergency conﬂ ict. Our 
study tries to reveal the amount of inappropriate use of vancomycin in a teaching 
hospital. METHODS: The study was conducted in a university hospital between 
February 2007 and May 2008. The hospital has 15 specialty and 5 subspecialty wards. 
a comprehensive questionnaire was designed. We random selected inpatients who 
received vancomycin. RESULTS: Forty four out of 45 patients had inappropriate 
indication and dose of vancomycin (97.7%). The most usage of vancomycin was 
recorded in hematology—oncology ward (71.11%) and then Intensive Care Unit 
(8.16%). Leukemia’s including Acute Myelogenous Leukemia (AML) and Acute Lym-
phoblastic Leukemia (ALL) were the most common reason of admission among 
patients. Cultures were negative (8.88%) despite great clinical evidence of infection. 
CONCLUSIONS: Vancomycin inappropriate use was high compared to other coun-
tries and it could be concerned as an area for implement educational and regulatory 
strategies by health policy makers to deal. However more detailed researches are 
needed to reveal the other aspects of this problem. Implementation of antibiotic 
protocols and standard treatment guidelines are recommended.
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THE COMMERCIAL EFFECTS OF REFORMULATIONS OF EXISTING 
DRUGS
Sepulveda B, Vincent L, White C
Quintiles, Hawthorne, NY, USA
OBJECTIVES: Given the high cost of creating a complete NME, it is not surprising 
that sixty percent of NDAs submitted to the FDA during the 1990s were for drugs 
based on an existing molecule (FDA, 2004). These products generally use three strate-
gies for life cycle management (LCM): chemical reformulation, new drug combina-
tions, or delivery reformulation, often resulting in an enhanced efﬁ cacy, safety, and 
compliance proﬁ le due to improved potency, tolerability, and duration of action. The 
objective of this study is to investigate the commercial effect of these LCM strategies. 
METHODS: Retail sales and prescription volume (TRx) of well-known reformula-
tions (venlafaxine to desvenlafaxine, citalopram to escitalopram, trazodone extended-
release, and paroxetine controlled-release) and reformulated combinations (esomepra-
zole/naproxen and ﬂ uticasone/salmeterol) were analyzed. Annual sales and TRx data 
were obtained since 2002 using SDI VONA. RESULTS: Interestingly, the two branded 
combination products analyzed had signiﬁ cant increases in TRx and in sales (P < 0.05) 
annually after the patent expiration of their original components, which showed 
signiﬁ cant annual decreases in sales and TRx (P < 0.05). The four reformulated 
products showed smaller changes than the combination products sales and TRx 
increases in the new branded products. Similarly, the utilization and sales decreases 
of the original components were smaller in the reformulated products than in the 
combinations. CONCLUSIONS: Given the higher cost of branded drugs, their unfa-
vorable tier placement by payers with respect to their generic counterparts and the 
increased pressure to reduce drug spending, it may not be surprising that reformulated 
generic products still enjoy sustained utilization. However, the premium for combina-
tion products that may increase patient adherence has not deterred utilization accord-
ing to the present ﬁ ndings.
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EFFECTIVENESS OF ANTIBACTERIAL THERAPY OPTIMIZATION BY 
CLINICAL PHARMACOLOGISTS
Eliseeva E1, Lozinskaya L2, Solodovnikov V3, Gainullina Y3
1Vladivostok State Medical University, Vladivostok, Russia; 2City Hospital #2, Vladivostok, 
Russia; 3Territory Fund of Compulsory Medical Insurance, Vladivostok, Russia
OBJECTIVES: antimicrobials are vital medicines, although their excessive use leads 
to resistance. Impact of clinical pharmacologists on the rational use of antibiotics is 
worth scientiﬁ c interest. The aim of the research: to analyze the dependence of the 
antibiotic therapy rationality on clinical pharmacologist’s administrative authority. 
METHODS: Segment of Territory Fund of Compulsory Medical Insurance database 
was analyzed including 51,128 informational units. Primarily we analyzed indications 
for separate antibiotis administration. Then rationality of antibiotic therapy according 
to nosologic classiﬁ cation was analyzed: pneumonia, chronic obstructive lung disease, 
acute cystitis, chronic pyelonephritis. The next step was a randomized analysis of 
antibacterial therapy rationality in three polyclinic groups. A clinical pharmacologist 
participated in antibiotic administrations in the 1st group of polyclinics. There was 
no clinical pharmacologist in the 2nd group. Clinical pharmacologist with administra-
tive authority controlled antimicrobials administration in the 3rd group. RESULTS: 
Low rationality of inhibitor-protected aminopenicillins, ciproﬂ oxacin, cefazolin use 
(64.82%, 23.39% and 1.77%) was revealed. At the same time inhibitor-protected 
penicillin’s administration frequency has increased in 1.5 times, and amoxicillin 
administration frequency has decreased in 5 times. It was found that the difference 
had been reliable only in the analysis of 2 groups: the ﬁ rst group of polyclinics (without 
clinical pharmacologist) and the 3rd group (participation of authorized clinical phar-
macologist) (P = 0.046). The least rational antibiotic’s administration was noted in 
patients with erysipelas (54.5%) and most rational antibacterial therapy was given to 
patients with acute cystitis (94.1%). Difference in physician’s preferences is reliable 
(P = 0.037) only comparing the 1st and the 3rd groups of policlinics. CONCLU-
SIONS: The highest rate of the rational antibacterial therapy was registered in poly-
clinics and nosologies if clinical pharmacologist with administrative authorities had 
participated in antibiotic therapy. Our research makes it possible to substantiate 
additional administrative authorities for a clinical pharmacologist. Authorized clinical 
pharmacologists will promote to enhance rationality of antibacterial therapy. 
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RATIONING IN PRACTICE- EQUITY IN WAITING TIMES FOR ELECTIVE 
SURGERY IN SWEDEN
Tinghög G, Andersson D
Linköping University, Linköping, Östergötland, Sweden
OBJECTIVES: Health care can be rationed by various mechanisms. In publicly funded 
health care systems referring patients to waiting lists is a common administrative way 
to ration care. However, there is little systematic knowledge on how rationing through 
waiting time actually affects access to care among different socioeconomic groups. 
And since rationing through waiting lists most often is done implicitly rather than 
explicitly there is an obvious risk that less powerful groups of patients get discrimi-
nated, resulting in a longer waiting time before being treated. The overall objective of 
this study was to explore the association between patients’ socioeconomic status, 
ethnical background and waiting time within non-acute surgical specialities. 
METHODS: Days on waiting list was used as dependant variable in a multiple regres-
sion model. This data was collected from the county council of Östergötland in 
Sweden (N = 4634). Data on disposable income, ethnicity and workforce activity were 
retrieved from national registers. RESULTS: Examining disposable income as a poten-
tial predictor, we found that lower disposable income was signiﬁ cantly associated with 
longer waiting time in orthopedics (P = 0.05) and general surgery (P = 0.05). In 
orthopedics, the lowest income group waited on average 28% longer than the highest 
income group. Examining ethnicity as a potential predictor, the only signiﬁ cant asso-
ciation found was in gynecology where patients with foreign origin surprisingly waited 
on average 40% shorter than patients with Swedish origin. For workforce activity, 
we found that patients excluded from the workforce were signiﬁ cantly associated with 
longer wait in ophthalmology. CONCLUSIONS: Our results reveal horizontal 
inequalities in access within several non-acute surgical specialties. However, the mere 
association between socioeconomic factors and inequalities in waiting times cannot 
alone support judgements about inequity. Hence, there is both a descriptive and 
normative question that needs to be assessed when investigating the reasonableness 
of rationing by waiting time.
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PATIENT ACCESS TO INNOVATIVE MEDICINES IN HUNGARY
Botlik O1, Kalotai Z1, Dessewffy Z1, Kalo Z2
1Novartis Hungary, Budapest, Hungary; 2Eötvös Loránd University, Budapest, Hungary
OBJECTIVES: Patient access to innovative medicines has critical importance from the 
societal perspective, pharmaceutical innovation contributes to increase in health 
capital. Delay in the pricing and reimbursement process limits the access of patients 
